secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2026-05-20T11:14:07+00:00
Accession:  0001764013-26-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16
--------------------------------------------------------------------------------

- IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.
- Cash $902.1M as of Mar 31, 2026; provides runway to potential launch of IMVT-1402 in GD.
- Net loss Q4 FY2026 $147.9M ($0.73/share) vs $106.4M ($0.64/share) YoY; FY net loss $505.6M ($2.77/share).
- Batoclimab discontinued after Phase 3 TED miss; $39M contract cost recognized in Q4.
- CLE proof-of-concept fully enrolled; topline data expected H2 2026. Other trials on track for GD, MG, CIDP, SjD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/0001764013-26-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm
  HTML page:      https://secwatch.observer/filing/0001764013-26-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer